Our work is possible thanks to:
Alzheimer's Research UK (2017-2020)
KCL-Hong Kong University PhD fund (2014-2018)
Alzheimer's Research UK (2015 and 2016)
Brain & Behavior Research Foundation(2014-2015)
National Institute on Aging NIA-NIH (2013-2017)
European Medical Information Network- EMIF-AD (2014-2017)
Medical Research Council MRC-NIHR NPC(2014-2016)
Alzheimer's Society (2012-2015 )
Libyan Education Council (2014-2017)
Saudi Education Council (2013-2016)
King's China Funding (2012-2016 )
The Roche Organ Transplantation Research Foundation (2013-2014 )
KCL-Hong Kong University partnership fund (2012)
Chinese Education Council (2010-2011 )
NIHR Biomedical Research Center for Mental Health (2009-2012 )
Department of Innovation, Universities and Skills (2008 )
KCL-National University Singapore cooperation fund (2008)
The Royal Academy of Engineering (2006 )
The Roche Organ Transplantation Research Foundation (2006 )
Marie Curie nework (RTN-2004 )
BBSRC PhD CASE award (2000-2004 )

Dementia - With a particular focus on the major debilitating neurodegenerative Alzheimer's Disease, the project aims to identify candidate molecules to act as clinical biomarkers. The projects current approach extracts small non protein molecules such as sugars, lipids and carbohydrates from biological tissues such as plasma and brain, before separating them on highly sensitive analytical systems, particularly HPLC, followed by accurate mass spectrometry, for example Q-TOF detection.  Statistical analysis is then applied enabling the isolation and identification of any molecule with biomarker qualities.
To date we have found that three lipids are diminished in the blood of AD patients. These molecules have great potential to diagnose cognitive decline and possibly early stage dementia and hence help to find treatments that are more successful. These and other biomarker molecules will be employed to stratify patients in new clinical trials for dementia.
Liver disease metabolism- With a particular focus on inflammation, the projects aim to quantitate a number of metabolites found in liver  and discover the paths involved in a range of liver deseases. We have detected new molecules related to liver injury and studied them during pre-retrieval ischaemia events during liver transplantation.
Big Data treatment - To integrate Lipidomics-Metabolomics and other -omics. Now working on longitudinal and large studies with +1000 participant/samples. The lab has analytical methods for the highthrouput scanning, the information obtained when counting for unidentified features is very big, per sample= 2k to 50K data points. We are designing new tools and protocols, focusing in data mining and validation.
Targeted- The specific analysis a number of molecules that are toxic to humans. Examples of projects are doping, drugs siezed from the internet, toxicity in cosmetics, insulins, adulterated herbal medicines, antibiotics and foods. We have worked with academics and also for the public, private companies, TV and police.
COLLABORATION EXAMPLE :
Inflammation metabolism- We have detected a molecule AMP related to lung injury and studied this in relation to nanoparticles such as those found in medicines or car fumes. We will now study the possibility of AMP and related molecules to diagnose a number of  conditions  such as asthma and allergies.
Research in the group is  multidisciplinary, with expertise ranging from synthetic and analytical chemistry, to molecular biology, bioinformatics and clinical applications
To find clinical biomarkers we  focus on liver and brain metabolism problems. Current projects are finding markers for Alzheimer's disease, cognition decline and aging, organ quality, herbal medicine metabolism, doping metabolism and inflammation cascades.
Some details for our recent findings can be seen below and in our publications.